Loading...

BHVN - Biohaven Pharmaceutical Holding Company Ltd.

Top Stock Signal for 05-13-2022
Loading Chart BHVN

Stock Signal Information


Signal

Top Stock Signal: BHVN
Report Date: 05-13-2022
Company: Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
Sector: Healthcare
Industry: Biotechnology

BHVN Technical Analysis

Company Contact

Biohaven Pharmaceutical Holding Company Ltd. (BHVN)
215 Church St
New Haven, CONNECTICUT 06510
Phone: 12034040410
Website: http://www.biohavenpharma.com
CEO: Mr. Vlad Coric

BHVN, Biohaven Pharmaceutical Holding Company Ltd.

BHVN Biohaven Pharmaceutical Holding Company Ltd. Logo Image

NYSE, New York Stock Exchange

Company Profile

Biohaven Pharmaceutical Holding Company Ltd., a clinical-stage biopharmaceutical company, develops late-stage products candidates targeting neurological diseases and rare disorders in the United States. Its clinical stage products include Rimegepant, a product that has completed phase III trials for acute treatment and prevention of migraine; Vazegepant that has completed Phase 2/3 trial for acute treatment and prevention of migraine; and Troriluzole that has completed II/III randomization phase and is ongoing extension trial for ataxias. The company also offers Troriluzole that is in phase II/III clinical stage for obsessive compulsive disorders and Alzheimer diseases; BHV-0223, a product for amyotrophic lateral sclerosis; BHV-5000, a product that has completed phase I clinical trial for neuropsychiatric disorders; and Verdiperstat, a product that is in phase III trial for multiple system atrophy. Biohaven Pharmaceutical Holding Company Ltd. has a collaboration agreement with Cove to facilitate telemedicine evaluation for migraine sufferers. The company was founded in 2013 and is headquartered in New Haven, Connecticut.

Top Stock Signals

best stock signal alert software, best stock signal service providers, options trade signals

About Top Stock Signals

Good stock signals have been found on this server. That is all we know.

Phone: +1 (407) 559-7228
Email: [email protected]

About Us | Newsletter | Members

Most Active
Top Gainers
Top Losers